

Attorney Docket No.: 49673 (72024)
U.S.S.N.: 09/537,859
Filed: March 28, 2002
Amendment and Response to Final Office Action
Page 3 of 10

MCP-2 polypeptide according to SEQ ID NO: 2, wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residues 1-2 and has chemokine antagonistic activity.

26. (New) An isolated amino-terminally truncated MCP-2 comprising residues 4-76 of an MCP-2 polypeptide according to MCP-2 (SEQ ID NO: 2), wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residues 1-3 and has chemokine antagonistic activity.
27. (New) An isolated amino-terminally truncated MCP-2 polypeptide comprising residues 5-76 of an MCP-2 polypeptide according to SEQ ID NO: 2 or 5, wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residues 1-4 and has chemokine antagonistic activity.
28. (New) The isolated amino-terminally truncated MCP-2 polypeptide of claims 24-27, wherein the truncated MCP-2 polypeptide is in glycosylated form.
29. (New) A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to any one of claims 24-27, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
30. (New) The pharmaceutical composition according to claim 29, wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.

RESPONSE

Pending claims

Claims 13-23 are pending. Upon entry of this Amendment and Response, claims 13-23